CITIC Securities International: Raise Rongchang Biology (09995.HK) target price to HK$112, maintain "buy" rating.

According to the Securities Times app, CICC released a research report stating that it has raised the target price of Rongchang Biotech (09995.HK) from 109 Hong Kong dollars to 112 Hong Kong dollars, and maintains a "buy" rating. In 2026, attention can be focused on the registration clinical development of Tezepelumab for asthma and Vituximab for ulcerative colitis; RC28 (approved for DME, applied for wAMD listing); PD-1/VEGF dual antibodies, CLND18.2ADC, and new type ADCRC278 continue to advance in early clinical trials, with potential BD opportunities.